ZVRA Overview

Zevra Therapeutics, Inc. is a commercial-stage rare disease company with a late-stage pipeline committed to bringing therapeutics to people living with rare diseases. Its commercial products and active development assets are MIPLYFFA, Arimoclomol, OLPRUVA, and Celiprolol. Its lead product, Niemann-Pick disease type C (NPC), is a rare, progressive neurodegenerative disorder. NPC is an ultra-rare and progressive neurodegenerative disease characterized by an inability of the body to transport cholesterol and lipids inside of cells. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of UCDs involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase. Celiprolol is a selective adrenoceptor modulator (SAM). Celiprolol is approved in certain EU states for the treatment of hypertension and angina.

Wall Street analysts forecast ZVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZVRA is24.00 USD with a low forecast of 21.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Zevra Therapeutics Inc revenue for the last quarter amounts to 36.22M USD, increased 77.54

Zevra Therapeutics Inc. EPS for the last quarter amounts to 0.63 USD, decreased -1150.00

Zevra Therapeutics Inc (ZVRA) has 61 emplpoyees as of June 21 2026.

Today ZVRA has the market capitalization of 762.58M USD.